6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
2018
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI